WO2009028663A1 - 抗Claudin-3抗体 - Google Patents

抗Claudin-3抗体 Download PDF

Info

Publication number
WO2009028663A1
WO2009028663A1 PCT/JP2008/065534 JP2008065534W WO2009028663A1 WO 2009028663 A1 WO2009028663 A1 WO 2009028663A1 JP 2008065534 W JP2008065534 W JP 2008065534W WO 2009028663 A1 WO2009028663 A1 WO 2009028663A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
fragment
cldn3
monoclonal antibody
claudin
Prior art date
Application number
PCT/JP2008/065534
Other languages
English (en)
French (fr)
Inventor
Kazuyasu Nakamura
Hiroshi Ando
Masayo Suzuki
Shinobu Kawamoto
Mariko Nakano
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of WO2009028663A1 publication Critical patent/WO2009028663A1/ja

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

　Claudin-3（以下、CLDN3と記す）遺伝子によりコードされるポリペプチドが関与する疾患に対する治療薬および診断薬として有用な、モノクローナル抗体または使用方法を提供することにある。 　本発明は、CLDN3の細胞外領域の立体構造を特異的に認識し、かつ該細胞外領域に結合するモノクローナル抗体または該抗体断片、該抗体を産生するハイブリドーマ、該抗体をコードするDNA、該DNAを含んでなるベクター、該ベクターを形質転換して得られる形質転換体、該ハイブリドーマまたは形質転換体を用いる抗体または抗体断片の製造方法、ならびに該抗体または抗体断片を用いるCLDN4およびCLDM3遺伝子によりコードされるポリペプチドが関与する疾患の診断薬または治療薬に関する。
PCT/JP2008/065534 2007-08-30 2008-08-29 抗Claudin-3抗体 WO2009028663A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-223802 2007-08-30
JP2007223802 2007-08-30

Publications (1)

Publication Number Publication Date
WO2009028663A1 true WO2009028663A1 (ja) 2009-03-05

Family

ID=40387373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065534 WO2009028663A1 (ja) 2007-08-30 2008-08-29 抗Claudin-3抗体

Country Status (1)

Country Link
WO (1) WO2009028663A1 (ja)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
CN103140501A (zh) * 2010-07-06 2013-06-05 加尼梅德药物公司 体内利用cldn6靶标定向之抗体的癌症治疗
CN103748112A (zh) * 2011-05-13 2014-04-23 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
WO2015136472A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
JP6077745B2 (ja) * 2009-09-30 2017-02-08 富士フイルムＲｉファーマ株式会社 抗ポドプラニン抗体、及び抗ポドプラニン抗体を含む医薬組成物
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
WO2018105560A1 (ja) * 2016-12-07 2018-06-14 国立大学法人大阪大学 Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
WO2018207638A1 (ja) * 2017-05-08 2018-11-15 国立大学法人大阪大学 抗ｃｌｄｎ－５抗体、及びその抗体を含有する医薬
US10407506B2 (en) 2014-03-12 2019-09-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
US10407507B2 (en) 2012-09-10 2019-09-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
US10604568B2 (en) 2013-07-31 2020-03-31 BioN Tech AG Diagnosis and therapy of cancer involving cancer stem cells
CN111087465A (zh) * 2019-12-24 2020-05-01 广州医科大学 一种针对密蛋白6的抗体偶联药物及应用
CN112204053A (zh) * 2018-03-28 2021-01-08 瑷备恩有限公司 特异性结合claudin 3的ecl-2的抗体，其片段及其用途
CN115433283A (zh) * 2017-09-06 2022-12-06 安斯泰来制药有限公司 用于癌症诊断的抗体
CN115433283B (zh) * 2017-09-06 2024-05-24 安斯泰来制药有限公司 用于癌症诊断的抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000032984A (ja) * 1998-05-15 2000-02-02 Eisai Co Ltd タイトジャンクション構成膜蛋白質クローディンファミリー
JP2003524384A (ja) * 1998-11-03 2003-08-19 アドヘレックス テクノロジーズ インコーポレイテッド クラウディン媒介機能を調節するための化合物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000032984A (ja) * 1998-05-15 2000-02-02 Eisai Co Ltd タイトジャンクション構成膜蛋白質クローディンファミリー
JP2003524384A (ja) * 1998-11-03 2003-08-19 アドヘレックス テクノロジーズ インコーポレイテッド クラウディン媒介機能を調節するための化合物および方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEWITT K.J. ET AL.: "The claudin gene family:expression in normal and neoplastic tissues", BMC CANCER, vol. 6, no. 186, 2006, pages 186 *
MORITA K. ET AL.: "Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands", PNAS, vol. 96, 1999, pages 511 - 516 *
OFFNER S. ET AL.: "Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy", CANCER IMMUNOL.IMMUNOTHER., vol. 54, no. 5, 2005, pages 431 - 445 *

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11473085B2 (en) 2009-02-20 2022-10-18 Ganymed Pharmaceuticals Gmbh Methods and compositions for diagnosis and treatment of cancer
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
JP6077745B2 (ja) * 2009-09-30 2017-02-08 富士フイルムＲｉファーマ株式会社 抗ポドプラニン抗体、及び抗ポドプラニン抗体を含む医薬組成物
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
US9932401B2 (en) 2009-11-11 2018-04-03 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
US10745477B2 (en) 2009-11-11 2020-08-18 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (CLDN6)
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
US11858988B2 (en) 2009-11-11 2024-01-02 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (CLDN6)
CN103140501A (zh) * 2010-07-06 2013-06-05 加尼梅德药物公司 体内利用cldn6靶标定向之抗体的癌症治疗
US10844133B2 (en) 2010-07-06 2020-11-24 Ganymed Pharmaceuticals Gmbh Cancer therapy using CLDN6 target-directed antibodies in vivo
US9718886B2 (en) 2010-07-06 2017-08-01 Ganymed Pharmaceuticals Ag Cancer therapy using CLDN6 target-directed antibodies in vivo
US9902778B2 (en) 2010-07-06 2018-02-27 Ganymed Pharmaceuticals Ag Cancer therapy using CLDN6 target-directed antibodies in vivo
US10233253B2 (en) 2011-05-13 2019-03-19 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US11859008B2 (en) 2011-05-13 2024-01-02 Ganymed Pharmaceuticals Gmbh Antibodies for treatment of cancer expressing claudin 6
US10919974B2 (en) 2011-05-13 2021-02-16 Ganymed Pharmaceuticals Gmbh Antibodies for treatment of cancer expressing claudin 6
CN107090043A (zh) * 2011-05-13 2017-08-25 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
CN107090043B (zh) * 2011-05-13 2021-12-07 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
CN103748112A (zh) * 2011-05-13 2014-04-23 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
US9321842B2 (en) 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
CN103748112B (zh) * 2011-05-13 2017-02-15 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
US10407507B2 (en) 2012-09-10 2019-09-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
US10414825B2 (en) 2012-09-10 2019-09-17 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
US10584177B2 (en) 2012-09-10 2020-03-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
US10604568B2 (en) 2013-07-31 2020-03-31 BioN Tech AG Diagnosis and therapy of cancer involving cancer stem cells
US11795218B2 (en) 2013-07-31 2023-10-24 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
US10654920B2 (en) 2014-03-12 2020-05-19 Prothena Biosciences Limited Anti-laminin4 antibodies specific for LG4-5
WO2015136472A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
US10889636B2 (en) 2014-03-12 2021-01-12 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
US10407506B2 (en) 2014-03-12 2019-09-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
WO2018105560A1 (ja) * 2016-12-07 2018-06-14 国立大学法人大阪大学 Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
JPWO2018105560A1 (ja) * 2016-12-07 2019-10-24 国立大学法人大阪大学 Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
US10882906B2 (en) 2016-12-07 2021-01-05 Osaka University Claudin 5 antibody, and medicine containing said antibody
JPWO2018207638A1 (ja) * 2017-05-08 2020-03-12 国立大学法人大阪大学 抗ｃｌｄｎ−５抗体、及びその抗体を含有する医薬
US11053313B2 (en) 2017-05-08 2021-07-06 Osaka University Anti-CLDN-5 antibody, and drug containing said antibody
JP7108956B2 (ja) 2017-05-08 2022-07-29 国立大学法人大阪大学 抗ｃｌｄｎ－５抗体、及びその抗体を含有する医薬
EP3623384A4 (en) * 2017-05-08 2021-01-27 Osaka University ANTI-CLDN-5 ANTIBODIES, AND THE MEDICINAL PRODUCT CONTAINING IT
WO2018207638A1 (ja) * 2017-05-08 2018-11-15 国立大学法人大阪大学 抗ｃｌｄｎ－５抗体、及びその抗体を含有する医薬
CN115433283A (zh) * 2017-09-06 2022-12-06 安斯泰来制药有限公司 用于癌症诊断的抗体
US11919951B2 (en) 2017-09-06 2024-03-05 Astellas Pharma Inc. Antibodies useful in cancer diagnosis
CN115433283B (zh) * 2017-09-06 2024-05-24 安斯泰来制药有限公司 用于癌症诊断的抗体
EP3778638A4 (en) * 2018-03-28 2022-05-04 Abion Inc. ANTIBODIES SPECIFICALLY BINDING CLAUDINE 3 ECL-2, FRAGMENT THEREOF AND USE THEREOF
CN112204053A (zh) * 2018-03-28 2021-01-08 瑷备恩有限公司 特异性结合claudin 3的ecl-2的抗体，其片段及其用途
CN111087465A (zh) * 2019-12-24 2020-05-01 广州医科大学 一种针对密蛋白6的抗体偶联药物及应用

Similar Documents

Publication Publication Date Title
WO2009028663A1 (ja) 抗Claudin-3抗体
WO2008114733A1 (ja) 抗Claudin-4抗体
HRP20192134T1 (hr) Molekule za vezanje na antigen koji veže egfr, vektori koji ih kodiraju, te njihove primjene
WO2010037837A3 (en) Bispecific single chain antibodies with specificity for high molecular weight target antigens
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
SG178567A1 (en) Affinity-matured humanized anti cea monoclonal antibodies
JP2013165711A5 (ja)
UA92580C2 (ru) Антитело, которое специфически связывается с cd22, и его терапевтическое и диагностическое применение
WO2008017963A3 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
WO2006087637A3 (en) Anti her2/neu antibody
JP2008508859A5 (ja)
MX2011003502A (es) Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
MX2012011405A (es) Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas.
JP2008520186A5 (ja)
NZ597692A (en) Anti-IGF antibodies
JP2007097598A5 (ja)
UA96141C2 (ru) Нейтрализующее антитело, которое имеет специфичность к человеческому il-6
NZ741567A (en) Antibodies for treatment of cancer expressing claudin 6
PH12012502376A1 (en) Modified antigen binding molecules with altered cell signaling activity
MY162131A (en) Single-chain multivalent binding proteins with effector function
JP2013523166A5 (ja)
WO2011020783A3 (en) Targeted immunoconjugates
RU2012143793A (ru) Биспецифические двухвалентные антитела анти-vegf/анти-ang-2
JP2010511388A5 (ja)
WO2007039818A8 (en) Antigen binding molecules having modified fc regions and altered binding to fc receptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828834

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08828834

Country of ref document: EP

Kind code of ref document: A1